Modality
Gene Therapy
MOA
BETi
Target
IL-13
Pathway
Tau
Ewing Sarcoma
Development Pipeline
Preclinical
~Jan 2015
→ ~Apr 2016
Phase 1
~Jul 2016
→ ~Oct 2017
Phase 2
Jan 2018
Phase 2Current
NCT06130608
721 pts·Ewing Sarcoma
2018-01→TBD·Terminated
721 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
2018
P2/3
Termina…
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06130608 | Phase 2/3 | Ewing Sarcoma | Terminated | 721 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα |